不同剂量阿托伐他汀治疗冠心病患者疗效观察

Efficacy of atorvastatin at different doses in patients with coronary heart disease

目的探讨不同剂量阿托伐他汀治疗冠心病患者的临床疗效。方法选取自2013年1月至2017年12月北部战区空军医院心内科收治的361例冠心病患者为研究对象。采用随机数字表法将其分为A组(n=181)与B组(n=180)。在常规治疗的基础上,A组患者行阿托伐他汀片20 mg/d治疗,B组患者行阿托伐他汀片40 mg/d治疗。比较两组患者治疗前后的血脂水平、肝功能指标水平、肾功能指标水平及治疗后的低密度脂蛋白胆固醇(LDL-C)达标率。结果治疗后,两组患者的血脂水平较治疗前均下降,但差异无统计学意义(P>0.05)。治疗后,两组患者肝功能、肾功能指标比较,差异均无统计学意义(P>0.05)。治疗后,两组患者的LDL-C达标率较治疗前均升高,且B组升高更为显著;各组治疗前后LDL-C达标率比较,差异均有统计学意义(P<0.05)。结论高剂量与常规剂量的阿托伐他汀均对冠心病患者有降脂疗效,对于血脂不达标的患者,高剂量阿托伐他汀对LDL-C达标率提高得更为显著,对患者的肝肾功能无显著影响,且安全性良好。

Objective To investigate the clinical efficacy of atorvastatin in patients with coronary heart disease.Methods A retrospective study was performed on 361 cases of patients with coronary heart disease who were admitted from January 2013 to December 2017.Patients were randomly divided into the Group A(n=181)and Group B(n=180).Patients in Group A were treated with atorvastatin tablets at 20 mg/day on the basis of conventional treatment,while patients in Group B were treated with atorvastatin tablets at 40 mg/day on the basis of conventional treatment.The blood lipid level,liver function level,kidney function level and low density lipoprotein cholesterol(LDL-C)after treatment were compared between the two groups.Results After treatment,the serum lipid levels of both Groups A and B were lower than those before treatment,with no statistically significant difference(P>0.05).There was no statistically significant difference between the hepatic and renal function levels and adverse reactions in both groups(P>0.05).After treatment,LDL-C in both groups was higher than that before treatment,and that in Group B was significantly higher,the LDL-C compliance rate before and after treatment had statistically significant difference(P<0.05).Conclusion Both high and conventional doses of atorvastatin have a lipid-lowering effect on patients with coronary heart disease.For patients with substandard blood lipids,high doses of atorvastatin have a more significant effect on LDL-C compliance rate,and have no significant effect on the liver and kidney functions of patients,with good safety.